AstraZeneca’s Crestor Pending At FDA For Atherosclerosis
This article was originally published in The Pink Sheet Daily
Executive Summary
Pivotal METEOR study indicates Crestor slows, but does not reverse, arterial plaque build-up in low-risk patients.